Warning: Undefined array key "network" in /hshare1/ZETTAI_path_WA_slash_usr_slash_proj_KARA/usr/proj/tcng/htdocs/tcng.php on line 565
Edge
EIF4EBP1 → CAPRIN2
Networks Including this Edge
| GSE10780_egf1520 - GSE10780 - SiGN-BN HC+Bootstrap | Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue |
| GSE12460_egf1520 - GSE12460 - SiGN-BN HC+Bootstrap | Expression profiling of neuroblastic tumors |
| GSE14208_egf1520 - GSE14208 - SiGN-BN HC+Bootstrap | Clinical response of metastatic gastric cancer patients to cisplatin and fluorouracil (CF) combination chemotherapy |
| GSE14210_egf1520 - GSE14210 - SiGN-BN HC+Bootstrap | Expression data from human endoscopic biopsy samples |
| GSE18864_egf1520 - GSE18864 - SiGN-BN HC+Bootstrap | Tumor expression data from neoadjuvant trial of cisplatin monotherapy in triple negative breast cancer patients |
| GSE23988_egf1520 - GSE23988 - SiGN-BN HC+Bootstrap | Expression data from breast cancer FNA biopsies from patients (US samples) |
| GSE25066_egf1520 - GSE25066 - SiGN-BN HC+Bootstrap | Genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE30375_egf1520 - GSE30375 - SiGN-BN HC+Bootstrap | Gene expression data from sorted and unsorted primary human acute myeloid leukemia (AML) samples |
| GSE31519_egf1520 - GSE31519 - SiGN-BN HC+Bootstrap | A Clinically Relevant Gene Signature in Triple-Negative and Basal-Like Breast Cancer |
| GSE4581_egf1520 - GSE4581 - SiGN-BN HC+Bootstrap | Gene Expression Profiles of Multiple Myeloma (N=414) Before Treatment |
